Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (RAVE)

Principal Investigator

John H. Stone | Johns Hopkins University | Baltimore, MD
Ulrich Specks | Mayo Clinic | Rochester, MN

Locations

Baltimore, MD
Rochester, MN
Birmingham, AL
Durham, NC
Boston, MA
Cleveland, OH
New York, NY
Groningen, Netherlands

Study Code

ITN021AI

Study Status

Completed

Abstract

Objectives: We will conduct a randomized, double-masked, placebo-controlled trial of rituximab, an anti-CD20 antibody, in ANCA-associated vasculitis (AAV). The trial has two major hypotheses:

  1. B cell depletion by rituximab induces stable remissions in AAV by re-establishing B cell tolerance to the ANCA target antigens
  2. Rituximab is as effective as the conventional treatment regimen for induction and maintenance of disease remission, and offers substantial advantages over standard therapy by virtue of its superior side-effect profile

Rationale: Activated B cells and autoantibodies to the target antigens proteinase or myeloperoxidase (ANCA) have been implicated in the pathogenesis of AAV. ANCA are produced by B cells and/or plasma cells. Rituximab effectively eliminates B cells for 6-12 months. Without their B cell precursors, short-lived plasma cells disappear after about 2 weeks. Thus, rituximab can be used to suppress antibody production and to disrupt other critical B cell contributions to disease. Treatment of AAV with rituximab should eliminate both the potentially pathogenic B cells and the disease-amplifying ANCA. Our preliminary data indicate rituximab is effective in inducing stable remission of AAV and that B cells returning after such therapy are tolerant to the ANCA target antigens in at least two thirds of patients.

Significance: Rituximab’s narrow spectrum of action provides novel opportunities to study the role of tolerance loss to the ANCA antigens in this disease. In addition, by challenging existing paradigms about conventional treatment (which is both toxic and unsuccessful in restoring tolerance), the proposed trial may may lead to a new standard regimen that is substantially safer.

Relevance to Immune Tolerance: Lessons from this trial and its mechanistic studies will vastly enhance our understanding of the pathogenesis of AAV by determining the conditions under which B cell tolerance can be restored. The findings may have important implications for many other autoimmune diseases.

Protocol summary: To test our hypotheses, we will perform a randomized, multi-center, double-masked, placebo-controlled trial in patients with generalized AAV. We will randomize 197 patients to either: 1) conventional treatment (cyclophosphamide and corticosteroids, followed by azathioprine); or 2) rituximab (plus corticosteroids, initially) for remission induction. The primary clinical comparison will be the ability of rituximab and corticosteroids to induce disease remissions, as measured by the cumulative disease activity at 6 months. Consistent with the standard duration of treatment for AAV, patients in the conventional therapy arm will receive cyclophosphamide for up to 6 months followed by azathioprine, to complete a total length of treatment of 18 months. In order to assess the ability of rituximab to restore B cell tolerance, patients in both arms of the trial will be followed for a total of 18 months.

[Clinicaltrials.gov]

Principal Investigator

John H. Stone | Johns Hopkins University | Baltimore, MD
Ulrich Specks | Mayo Clinic | Rochester, MN

Locations

Baltimore, MD
Rochester, MN
Birmingham, AL
Durham, NC
Boston, MA
Cleveland, OH
New York, NY
Groningen, Netherlands

Articles

Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, Jayne D, Smith RM, Rosenkranz A, Specks U, Stone JH, Kronbichler A; RAVE−ITN Research Group.. (2023) Risk factors for serious infections in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, Epub ahead of print. DOI: 0.1136/ard-2022-223401 PMID: 36702528. [PubMed] [Reprint]
Monach PA, Warner RL, Lew R, Tomasson G, Specks U, Stone JH, Fervenza FC, Hoffman GS, Kallenberg CGM, Langford CA, Seo P, St Clair EW, Spiera R, Johnson KJ, Merkel PA. (2022) Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-Associated Vasculitis. ACR Open Rheumatology, 4 (2), 168-176. DOI: doi.org/10.1002/acr2.11366 PMID: 34792864 PMCID: PMC8843765 [PubMed] [Reprint]
Berti A, Hillion S, Hummel AM, Son YM, Chriti N, Peikert T, Carmona EM, Abdulahad WH, Heeringa P, Harris KM, St Clair EW, Brunetta P, Fervenza F, Langford C, Kallenberg C, Merkel P, Monach PA, Seo P, Spiera RF, Stone JH, Grandi G, Sun J, Pers JO, Specks U, Cornec D. (2021) Circulating autoreactive proteinase 3 + B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 6 (22), e150999. DOI: 10.1172/jci.insight.150999 PMID: 34618687 PMCID: PMC8663783 [PubMed] [Reprint]
Owczarczyk K, Cascino M, Holweg C, Tew GW, Ortmann W, Behrens T, Schindler T, Langford CA, St Clair EW, Merkel PA, Spiera R, Seo P, Kallenberg CG, Specks U, Lim N, Stone J, Brunetta P, Prunotto M, RAVE-ITN Research Group. (2020) Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight, 5 (18), e136180. DOI: 10.1172/jci.insight.136180 PMID: 32841219 PMCID: PMC7526555 [PubMed] [Reprint]
Thompson GE, Fussner LA, Hummel AM, Schroeder DR, Silva F, Snyder MR, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Specks U. (2020) Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Front Immunol, 11, 2053. DOI: 10.3389/fimmu.2020.02053 PMID: 33013868 PMCID: PMC7495134 [PubMed] [Reprint]
Bensalem A, Mulleman D, Paintaud G, Azzopardi N, Gouilleux-Gruart V, Cornec D, Specks U, Ternant D. (2020) Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. Clin Pharmacokinet., 59 (4), 519-530. DOI: 10.1007/s40262-019-00826-5 PMID: 31586310 [PubMed]
Berti A, Warner RL, Johnson KJ, Cornec D, Schroeder DR, Kabat BF, Langford CA, Kallenberg CGM, Seo P, Spiera RF, St Clair EW, Fervenza FC, Stone JH, Monach PA, Specks U, Merkel PA, RAVE-ITN Research Group. (2019) The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. J Autoimmun, epub ahead of print. DOI: 10.1016/j.jaut.2019.07.001 PMID: 31320177 [PubMed]
Kronbichler A, Leierer J, Shin JI, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman M, Kallenberg CGM, St Clair EW, Brunetta P, Fervenza FC, Geetha D, Keogh KA, Monach PA, Ytterberg SR, Mayer G, Specks U, Stone JH, RAVE-ITN Research Group. (2019) The Association of Pulmonary Haemorrhage, Positive PR3-ANCA and Urinary Red Blood Cell Casts with Venous Thromboembolism in ANCA-Associated Vasculitis. Arthritis Rheumatol., epub ahead of print. DOI: 10.1002/art.41017 PMID: 31216123 [PubMed]
Wallace ZS, Fu X, Liao K, Kallenberg CGM, Langford CA, Merkel PA, Monach P, Seo P, Specks U, Spiera R, St Clair EW, Zhang Y, Choi H, Stone JH. (2019) Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis.. Arthritis Rheumatol, epub ahead of print. DOI: 10.1002/art.41006 PMID: 31162829 [PubMed]
Merkel PA, Monach PA, Carette S, Cuthbertson D, Hoffman GS, Langford CA, Specks U, Spiera RF, St Clair EW, Stone JH, Ytterberg SR, Xie G, Ji X, Ciavatta DJ, Byun J, Pinder BD, Zhao A, Zhang J, Tadesse Y, Qian D, Weirauch M, Nair R, Tsoi A, Pagnoux C, Chung S, Davis JC Jr, Dellaripa PF, Forbess L, Gewurz-Singer O, Khalidi N, Koening C, Mahr AD, McAlear C, Moreland L, Seo EP, Sreih A, Elder JT, Qu J, Ochi T, Hirano N, Edberg JC, Falk RJ, Amos CI, Siminovitch KA; Vasculitis Clinical Research Consortium. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol, 69 (5), 1054-66. DOI: 10.1002/art.40034 PMID: 28029757 PMCID: PMC5434905 [PubMed] [Reprint]
Geetha D, Specks U, Kallenberg CGM, Lim N, Spiera R, St Clair EW, Merkel PA, Seo P, Monach PA, Fessler BJ, Langford CA, Hoffman GS, Stone JH, Sethi S, De Vriese AS, Lepori N, Sharma R, Fervenza FC; RAVE-ITN Research Group. (2017) Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. Am J Nephrol. DOI: 10.1159/000480443 PMID: 28881339 [PubMed] [Reprint]
Miloslavsky EM, Lu N, Unizony S, Choi HK, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Fervenza F, Monach PA, Specks U, Stone JH. (2016) Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis Rheumatol, 68 (12), 2945-52. DOI: 10.1002/art.39812 PMID: 27428559 PMCID: PMC5541999 [PubMed] [Reprint]
Clain JM, Hummel AM, Stone JH, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, McCune WJ, Specks U; WGET and RAVE-ITN Research Groups. (2017) Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clin Exp Immunol, 188 (1), 174-81. DOI: 0.1111/cei.12925 PMID: 28076879 PMCID: PMC5343341 [PubMed] [Reprint]
Unizony S, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Monach PA, Fervenza F, Stone JH, Specks U; RAVE-ITN Research Group, Villarreal M, Kallenberg CM, Choi HK1. (2017) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis, 75 (6), 1166-9. DOI: 10.1136/annrheumdis-2015-208073 PMID: 26621483 PMCID: PMC4908815 [PubMed] [Reprint]
Pepper RJ, Draibe JB, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, Monach PA, Seo P, Spiera R, St Clair EW, Tchao NK, Stone JH, Specks U, Merkel PA, Caplin B, Salama AD; RAVE-ITN Research Group. (2017) Association of serum calprotectin (S100A8/S100A9) levels with disease relapses in PR3-ANCA-associated vasculitis. Arthritis Rheumatol, 69 (1), 185-93. DOI: 10.1002/art.39814 PMID: 27428710 [PubMed] [Reprint]
Cartin-ceba R, Indrakanti D, Specks U, Stone JH, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Spiera RF, Monach PA, Seo P, Tchao NK, Ytterberg SR, St Clair W, Brunetta PG, Song H, Birmingham D, Rovin BH; RAVE-ITN Research Group. (2017) The pharmacogenomic association of Fcγ receptors and cytochrome p450 enzymes and response to treatment with rituximab or cyclophosphamide in Anti-Neutrophil Cytoplasmic Antibody-Associated vasculitis. Arthritis Rheumatol, 69 (1), 169-75. DOI: 10.1002/art.39822 PMID: 27482943 [PubMed] [Reprint]
Wallace ZS, Miloslavsky EM, Cascino M, Unizony SH, Lu N, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Brunetta P, Choi HK, Stone JH. (2017) Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA-Associated Vasculitis. Arthritis Care Res (Hoboken)., 69 (7), 1001-10. DOI: 10.1002/acr.23099 PMID: 27696762 PMCID: PMC5611860 [PubMed] [Reprint]
Hummel AM, Cartin-ceba R, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Tchao NK, Stone JH, Fussner LA, Schroeder DR, Silva F, Snyder MR, Specks U; RAVE-ITN Research Group.. (2016) Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol, 68 (7), 1700-10. DOI: 10.1002/art.39637 PMID: 26882078 [PubMed] [Reprint]
Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.. (2015) Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol, 26 (4), 796-85. DOI: 10.1681/ASN.2014010046 PMID: 25381429 PMCID: PMC4378104 [PubMed] [Reprint]
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Ikle D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.. (2015) Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol, 67 (6), 1629-36. DOI: 10.1002/art.39104 PMID: 25776953 [PubMed] [Reprint]
Grayson PC, Carmona-Rivera C, Xu L, Lim N, Gao Z, Asare AL, Specks U, Stone JH, Seo P, Spiera RF, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ytterberg SR, Phippard DJ, Merkel PA, Kaplan MJ, Monach PA; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. (2015) Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol, 67 (7), 1922-32. DOI: 10.1002/art.39153 PMID: 25891759 PMCID: PMC4485551 [PubMed] [Reprint]
Unizony S, Lim N, Phippard DJ, Carey VJ, Miloslavsky EM, Tchao NK, Ikle D, Asare AL, Merkel PA, Monach PA, Seo P, St Clair EW, Langford CA, Spiera R, Hoffman GS, Kallenberg CG, Specks U, Stone JH.. (2015) Peripheral CD5+ B-cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol, 67 (2), 535-44. DOI: 10.1002/art.38916 PMID: 25332071 PMCID: PMC4497572 [PubMed] [Reprint]
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Tchao NK, Viviano L, Ding L, Ikle D, Villareal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. (2014) Rituximab for the Treatment of Relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol, 66 (11), 3151-59. DOI: 10.1002/art.38788 PMID: 25047592 PMCID: PMC4229846 [PubMed] [Reprint]
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Ikle D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH, for the Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. (2013) Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis Rheum, 65 (9), 2441-9. DOI: 10.1002/art.38044 PMID: 23754238 PMCID: PMC4949954 [PubMed] [Reprint]
Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH for the RAVE-ITN Research Group. (2013) Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. N Engl J Med, 369 (5), 417-27. DOI: 10.1056/NEJMoa1213277 PMID: 23902481 [PubMed] [Reprint]
Monach PA, Kumpers P, Lukasz A, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Carette S, Ding L, Hoffman GS, Ikle D, Kallenberg CG, Khalidi NA, Langford CA, Seo P, St. Clair EW, Spiera R, Tchao N, Ytterberg SR, Haubitz M, Merkel PA. (2012) Circulating angiopoietin-2 as a biomarker in ANCA-associated Vasculitis. PLoS One, 7 (1), e30197. DOI: 10.1371/journal.pone.0030197 PMID: 22279570 PMCID: 3261176 [PubMed] [Reprint]
Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St. Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA. (2011) Circulating markers of vascular injury and angiogenesis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheum, 36 (12), 3988-97. DOI: 10.1002/art.30615 PMID: 21953143 PMCID: PMC3227746 [PubMed] [Reprint]
Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, Kallenberg CGM, St. Clair EW, Ding L, Webber L, Mokhtarani M, Tchao NK, Sayre PH, Seyfert-Margolis V, Ikle D, Brunetta P, Zhang D, Sejismundo L, Mueller M, Stone JH. (2011) Design of the Rituximab in ANCA-associated Vasculitis (RAVE) Trial. The Open Arthritis Journal, 4 (1), 1-18. [Reprint]
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New Eng J Med, 363 (3), 221-32. DOI: 10.1056/NEJMoa090990 PMID: 20647199 PMCID: PMC3137658 [PubMed] [Reprint]
Kimberly RP. (2015) The Road Traveled: Genomics and Biomarkers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol, 67 (7), 1700-2. DOI: 10.1002/art.39148 PMID: 25891203 [PubMed] [Reprint]

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility